Stefan Glück

Author PubWeight™ 35.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol 2006 1.81
2 Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer. Psychosom Med 2008 1.27
3 Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013 1.26
4 Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer 2013 1.23
5 Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 2013 1.21
6 Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2012 1.17
7 A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009 1.14
8 Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008 1.14
9 Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010 1.14
10 Participation in cancer clinical trials: why are patients not participating? Med Decis Making 2013 1.10
11 Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat 2014 1.05
12 Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer. Clin Cancer Res 2006 1.02
13 Primary ectopic breast cancer presenting as a vulvar mass. Clin Breast Cancer 2006 1.01
14 Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 2011 0.95
15 Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat 2012 0.95
16 Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol 2011 0.90
17 A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 2011 0.90
18 Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida. Int J Behav Med 2014 0.89
19 Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. Med Oncol 2014 0.86
20 Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 2011 0.86
21 Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs 2013 0.85
22 Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag 2008 0.85
23 A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2012 0.84
24 Chemoprevention of breast cancer. Expert Rev Anticancer Ther 2008 0.84
25 Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) 2011 0.83
26 Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 2010 0.83
27 Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer? Expert Opin Ther Targets 2012 0.83
28 Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol 2012 0.83
29 Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells 2005 0.82
30 Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat 2014 0.81
31 Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 2012 0.79
32 Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat 2010 0.79
33 Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 2012 0.78
34 Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med 2016 0.78
35 Gene expression profiling in breast cancer. Am J Transl Res 2013 0.77
36 Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol 2004 0.77
37 Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep 2012 0.77
38 Introduction to special issue translational goals of neoadjuvant therapy. Breast Cancer Res Treat 2012 0.75
39 Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Clin Adv Hematol Oncol 2008 0.75
40 Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro. Stem Cells Dev 2004 0.75
41 Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers 2013 0.75